FOR THE NEXT GENERATION OF PHYSICIANS
← All USMLE guides
HEMATOLOGY AND ONCOLOGY

Myeloproliferative neoplasms: polycythemia vera, ET and myelofibrosis.

JAK2 V617F, erythromelalgia, phlebotomy and hydroxyurea, teardrop cells and the causes of secondary polycythemia.

Myeloproliferative neoplasms overproduce mature cells from a clonal stem cell. JAK2 mutation is the key.

Polycythemia vera

JAK2 V617F in most patients. Pruritus after a hot bath, facial plethora, splenomegaly, thrombosis and low erythropoietin. Treat with phlebotomy and low-dose aspirin, and hydroxyurea for high-risk disease. Secondary polycythemia has high erythropoietin from hypoxia, renal tumors or testosterone.

Essential thrombocythemia

Sustained high platelet count with erythromelalgia, thrombosis and bleeding. JAK2, CALR or MPL mutations; hydroxyurea in high risk.

Primary myelofibrosis

Marrow fibrosis with teardrop cells, massive splenomegaly and extramedullary hematopoiesis. Dry tap on aspiration; ruxolitinib helps. Polycythemia vera can progress to this state or to acute leukemia.

Keep going in hematology and oncology

Related on USMLE WEB

Frequently asked questions

Which mutation drives polycythemia vera?

JAK2 V617F.

How is polycythemia vera treated?

Phlebotomy and aspirin, with hydroxyurea for high risk.